A First-in-human Study of PRTH-101 Monotherapy +/- Pembrolizumab in Subjects With Advanced Malignancies

This first-in-human study is testing a new cancer drug called PRTH-101, alone or combined with pembrolizumab (a well-known immunotherapy), in people with advanced cancers that have stopped responding to other treatments. **You may be eligible if...** - You are 18 or older - You have advanced or metastatic cancer that cannot be removed surgically - Your cancer has measurable disease on imaging - You have already tried available treatments and your cancer is still progressing - Your general health is stable enough to participate **You may NOT be eligible if...** - You have hepatocellular carcinoma (liver cancer), sarcoma, or glioma - Your cancer is not measurable on imaging - Your cancer has not previously been treated - You have significant organ dysfunction or other health conditions that would make participation unsafe Talk to your doctor to see if this trial is right for you.